A Universal Biomarkerfor cancer
Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We are developing a universal biomarker for enabling oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).
What’s New at Travera
MEDFORD, MASSACHUSETTS – November 2, 2021 – Travera announced today the publication of the results of a study which confirms the potential clinical utility of the company's testing approach to predicting a patient's response to cancer drugs based on subtle changes in...
MEDFORD, MASSACHUSETTS – October 26, 2021 – Travera announced today that it has received certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA)...
MEDFORD, MASSACHUSETTS – July 15, 2021 – Travera, Inc. has announced that it has recently closed a $5.5 million Series A Extension. The financing was led by Khosla Ventures and joined by existing investor Horizons Ventures and a new investor in the company, MSA...
Read our white paper
Travera’s solution is to try drugs on the OUTSIDE of the patient rather than INSIDE. That is, remove some of the cancer cells from the patient and apply the drugs to these removed (“ex vivo”) cancer cells. We can then try many different cancer drugs (in very small quantities) against these cancer cells. This approach completely eliminates toxicity, dramatically reduces the cost (because we only need enough drug to treat a few cells, not a whole person), and only takes a couple of days.